Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
risvutatug
- Development stage
- Unknown
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Risvutatug (also referred to by the machine-translated name livototamab) is a fully human monoclonal antibody targeting B7-H3 (CD276), an immune checkpoint ligand overexpressed in various solid tumors. It is developed as the antibody-drug conjugate (ADC) risvutatug rezetecan (HS-20093 / GSK5764227), where risvutatug is covalently linked to rezetecan, an exatecan-derived topoisomerase I inhibitor payload, via a cleavable tetrapeptide linker. Upon binding to B7-H3 on tumor cells, the ADC is internalized, releasing the topoisomerase I inhibitor to induce DNA damage and apoptosis. Originally developed by Hansoh Pharma and licensed globally (excluding Greater China) to GSK, risvutatug rezetecan is in Phase III clinical trials for small cell lung cancer (SCLC) and osteosarcoma, and in Phase II trials for other solid tumors including prostate cancer and non-small cell lung cancer.
- Other names
- livototamabrisvutatug rezetecan瑞康立伏妥塔单抗立伏妥塔单抗
02
Targets
B7-H3
Beyond the preview
Go deeper on risvutatug.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on risvutatug.